Detalhe da pesquisa
1.
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).
Ann Oncol
; 29(4): 985-991, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29346507
2.
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Ann Oncol
; 28(9): 2219-2224, 2017 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28911062
3.
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Ann Oncol
; 28(10): 2526-2532, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961833
4.
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Ann Oncol
; 27(8): 1585-93, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27084954